论文部分内容阅读
目的探讨降纤酶联合丹参川芎嗪注射液治疗急性缺血性脑卒中的临床疗效。方法选取阳新县富池中心血防站2012年1月—2014年3月收治的82例急性缺血性脑卒中患者,按照数字随机表法将患者分为观察组和对照组,每组41例。对照组给予常规治疗,观察组在此基础上加用降纤酶联合丹参川芎嗪注射液治疗。治疗3个月后,比较两组患者的临床疗效、神经功能缺损程度评分、Barthel指数、病死率及不良反应。结果观察组患者总有效率(92.7%)高于对照组(73.2%),差异有统计学意义(P<0.05)。观察组患者神经功能缺损程度评分低于对照组,Barthel指数高于对照组,差异有统计学意义(P<0.05)。观察组患者病死率为4.9%(2/41),低于对照组的22.0%(9/41),差异有统计学意义(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论降纤酶联合丹参川芎嗪注射液治疗急性缺血性脑卒中疗效确切,有助于降低患者病死率。
Objective To investigate the clinical efficacy of defibrase combined with Salviae miltiorrhizae ligustrazine injection in the treatment of acute ischemic stroke. Methods Eighty-two acute ischemic stroke patients were selected from Fuchi Central Blood Stasis Station in Yangxin County from January 2012 to March 2014, and divided into observation group and control group according to the digital random table method, with 41 cases in each group. Control group given conventional treatment, the observation group on the basis of plus defibrase plus Salvia ligustrazine injection. After 3 months of treatment, the clinical efficacy, neurological deficit score, Barthel index, mortality and adverse reactions were compared between the two groups. Results The total effective rate (92.7%) in observation group was higher than that in control group (73.2%), the difference was statistically significant (P <0.05). The score of neurological deficit in observation group was lower than that in control group, Barthel index was higher than that in control group, the difference was statistically significant (P <0.05). The case fatality rate in the observation group was 4.9% (2/41), which was lower than that in the control group (22.0%, 9/41). The difference was statistically significant (P <0.05). Two groups of patients with adverse reactions, the difference was not statistically significant (P> 0.05). Conclusion Defibrase combined with Salvia Ligustrazine injection in the treatment of acute ischemic stroke exact effect, contribute to reducing patient mortality.